Acquisitions and License Agreements (Schedule of Intangible Assets Acquired) (Details) - USD ($) $ in Millions	Aug. 31, 2016	Feb. 01, 2016	Sep. 25, 2015	Apr. 16, 2015	Aug. 14, 2014	Mar. 19, 2014
Hemostasis Products
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired		$ 173.5
Intangible assets		$ 132.7
Therakos
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired			$ 1,019.1
Intangible assets			1,170.0
Therakos | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired			$ 1,170.0
Intangible assets acquired, weighted-average useful life			15 years
Ikaria
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired				$ 1,253.6
Intangible assets				1,971.0
Amortizable intangible assets acquired				1,971.0
Ikaria | In-process research and development
Intangible Assets Acquired as Part of Business Combination [Line Items]
Indefinite lived intangible assets acquired				$ 81.0
Ikaria | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life				15 years
Amortizable intangible assets acquired				$ 1,820.0
Ikaria | Trademarks
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life				22 years
Amortizable intangible assets acquired				$ 70.0
Cash flow discount rate				14.50%
Questcor Pharmaceuticals, Inc.
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired					$ 5,786.5
Intangible assets					5,601.1
Questcor Pharmaceuticals, Inc. | In-process research and development
Intangible Assets Acquired as Part of Business Combination [Line Items]
Indefinite lived intangible assets acquired					$ 218.3
Cash flow discount rate					16.00%
Questcor Pharmaceuticals, Inc. | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life					18 years
Amortizable intangible assets acquired					$ 5,343.3
Cash flow discount rate					14.50%
Questcor Pharmaceuticals, Inc. | Trademarks
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life					13 years
Amortizable intangible assets acquired					$ 5.2
Cash flow discount rate					10.00%
Questcor Pharmaceuticals, Inc. | Customer relationships
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life					12 years
Amortizable intangible assets acquired					$ 34.3
Cash flow discount rate					10.00%
Cadence Pharmaceuticals, Inc.
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired						$ 1,329.2
Intangible assets						$ 1,300.0
Cash flow discount rate						13.00%
Cadence Pharmaceuticals, Inc. | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life						8 years
Amortizable intangible assets acquired						$ 1,300.0
Stratatech [Member]
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired	$ 76.0
Intangible assets	$ 99.8
StrataGraft [Member] | Stratatech [Member] | In-process research and development
Intangible Assets Acquired as Part of Business Combination [Line Items]
Cash flow discount rate	16.50%
Raplixa [Member] | Hemostasis Products | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life		15 years
Amortizable intangible assets acquired		$ 73.0
Cash flow discount rate		17.00%
Therakos Immunotherapy | Therakos | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Cash flow discount rate			17.00%
Inomax | Ikaria | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Cash flow discount rate				14.50%
Terlipressin [Member] | Ikaria | In-process research and development
Intangible Assets Acquired as Part of Business Combination [Line Items]
Cash flow discount rate				17.00%
Recothrom [Member] | Hemostasis Products | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life		13 years
Amortizable intangible assets acquired		$ 42.7
Cash flow discount rate		16.00%
PreveLeak [Member] | Hemostasis Products | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life		13 years
Amortizable intangible assets acquired		$ 17.0
Cash flow discount rate		17.00%